

## Xbrane Biopharma - Still A Hidden Gem

Redeye remains positive on the investment case in Xbrane Biopharma following its Q3 2022 report. Only a few weeks remain until the anticipated approval of Ximluci by the European Commission, bringing the Q1 2023 launch in Europe closer. 2023 will be a pivotal year for Xbrane, and the share price is likely to follow, we judge.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

### Attachments

---

[Xbrane Biopharma - Still A Hidden Gem](#)